Wall Street is positive on Outlook Therapeutics Inc (OTLK). On average, analysts give the stock a Strong Buy rating. The average price target is $7, which means analysts expect the stock to climb by 438.46% over the next twelve months.
That average ranking earns the stock an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating OTLK a Strong Buy today. Find out what this means to you and get the rest of the rankings on OTLK!
Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.
InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.
What's Happening With Outlook Therapeutics Inc Stock Today?
Outlook Therapeutics Inc (OTLK) stock is down -2.26% while the S&P 500 has gained 0.63% as of 10:12 AM on Monday, Dec 6. OTLK is down -$0.03 from the previous closing price of $1.33 on volume of 391,714 shares. Over the past year the S&P 500 is up 23.70% while OTLK has gained 13.04%. OTLK lost -$0.36 per share the over the last 12 months.
Click Here to get the full Stock Report for Outlook Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
